NO20034020L - Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler - Google Patents

Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler

Info

Publication number
NO20034020L
NO20034020L NO20034020A NO20034020A NO20034020L NO 20034020 L NO20034020 L NO 20034020L NO 20034020 A NO20034020 A NO 20034020A NO 20034020 A NO20034020 A NO 20034020A NO 20034020 L NO20034020 L NO 20034020L
Authority
NO
Norway
Prior art keywords
compounds
mhc
diagnosis
therapy
methods
Prior art date
Application number
NO20034020A
Other languages
English (en)
Other versions
NO20034020D0 (no
Inventor
Lars Winther
Lars Oestergaard Petersen
Soeren Buus
Joergen Schoeller
Erik Ruud
Oeystein Aamellem
Original Assignee
Dynal Biotech Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynal Biotech Asa filed Critical Dynal Biotech Asa
Publication of NO20034020D0 publication Critical patent/NO20034020D0/no
Publication of NO20034020L publication Critical patent/NO20034020L/no

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y10/00—Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
NO20034020A 2001-03-14 2003-09-11 Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler NO20034020L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US27544701P 2001-03-14 2001-03-14
US27547001P 2001-03-14 2001-03-14
US27544801P 2001-03-14 2001-03-14
DKPA200100435 2001-03-14
DKPA200100436 2001-03-14
DKPA200100441 2001-03-14
PCT/DK2002/000169 WO2002072631A2 (en) 2001-03-14 2002-03-13 Mhc molecule constructs and their usesfor diagnosis and therapy

Publications (2)

Publication Number Publication Date
NO20034020D0 NO20034020D0 (no) 2003-09-11
NO20034020L true NO20034020L (no) 2003-11-06

Family

ID=27545247

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20034020A NO20034020L (no) 2001-03-14 2003-09-11 Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler

Country Status (8)

Country Link
EP (2) EP2336167B1 (no)
JP (2) JP4608184B2 (no)
AU (2) AU2002240818C1 (no)
CA (1) CA2440773A1 (no)
DK (1) DK2336167T3 (no)
ES (1) ES2747357T3 (no)
NO (1) NO20034020L (no)
WO (1) WO2002072631A2 (no)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009003492A1 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
GB0125093D0 (en) * 2001-10-18 2001-12-12 Univ Southampton Multimeric proteins
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
JP2003294753A (ja) * 2002-04-01 2003-10-15 Kyokuto Seiyaku Kogyo Kk 凝集反応増感剤、免疫測定用試薬及び免疫測定法
US20040018495A1 (en) * 2002-07-24 2004-01-29 Xing-Xiang Li Microparticle based signal amplification for the detection of analytes
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
DE602004024285D1 (de) * 2003-02-05 2010-01-07 Gen Hospital Corp System auf mikrochipbasis zur hiv-diagnostik
WO2004072112A2 (en) * 2003-02-11 2004-08-26 Københavns Universitet A method for formulating mhc-like molecules for long time storage
AU2004243881B2 (en) * 2003-05-27 2010-07-15 Pointcare Technologies, Inc. Enhanced cellular assay method for use in flow cytometry or similar instruments using optically resonant particles
WO2005017525A1 (en) * 2003-08-04 2005-02-24 Emory University Porous materials embedded with nanospecies
ES2395818T3 (es) * 2004-07-13 2013-02-15 Charite - Universitatsmedizin Berlin Composición que comprende un agente farmacológicamente activo acoplado a un componente específico de célula diana, y una saponina
PT2397156T (pt) 2005-06-08 2016-12-23 The President And Fellows Of Harvard College Métodos e composições para tratamento de infeções persistentes e cancro através da inibição da via de morte celular programada 1 (pd-1)
US20090061478A1 (en) * 2006-01-30 2009-03-05 Lene Have Poulsen High-Speed Quantification of Antigen Specific T-Cells in Whole Blood by Flow Cytometry
KR20090041360A (ko) 2006-02-27 2009-04-28 테크니쉐 유니베르시테트 뮌헨 암 영상화 및 치료방법
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2127664A1 (en) * 2008-02-15 2009-12-02 Max-Delbrück-Centrum Change of the load state of MHC molecules by dipeptides
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
DK2362882T3 (en) * 2008-11-03 2016-02-22 Sanquin Bloedvoorziening Detection of antigenfølsomme cells in a sample
KR101721707B1 (ko) 2008-11-28 2017-03-30 에모리 유니버시티 감염 및 종양 치료 방법
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
JP5799394B2 (ja) 2009-03-18 2015-10-28 オンコセラピー・サイエンス株式会社 Ｎｅｉｌ３ペプチドおよびそれを含むワクチン
ES2486673T3 (es) 2009-03-19 2014-08-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Uso de NKp46 para prevenir la diabetes tipo I
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
SG10201501857YA (en) 2010-03-11 2015-05-28 Oncotherapy Science Inc Hjurp Peptides And Vaccines Including The Same
TWI538685B (zh) 2010-04-02 2016-06-21 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
EP2404618A1 (en) * 2010-07-07 2012-01-11 Stichting Katholieke Universiteit meer in het bijzonder Radboud Universiteit Nijmegen Immunomodulatory protein constructs with a helical polymeric backbone.
CN103502425A (zh) * 2011-04-11 2014-01-08 学校法人东邦大学 细胞粘附性光控制基材
MX355759B (es) 2011-10-28 2018-04-27 Oncotherapy Science Inc Peptidos topk y vacunas que incluyen los mismos.
WO2013140393A1 (en) 2012-03-21 2013-09-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides derived from the d1 - domain of nkp46
WO2014058915A2 (en) 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
KR102208505B1 (ko) 2012-12-11 2021-01-27 앨버트 아인슈타인 컬리지 오브 메디신 고처리량 수용체:리간드 확인을 위한 방법
TWI658049B (zh) 2013-03-12 2019-05-01 腫瘤療法 科學股份有限公司 Ｋｎｔｃ２胜肽及含此胜肽之疫苗
WO2014191839A2 (en) * 2013-05-14 2014-12-04 Oslo Universitetssykehus Hf Detection of gluten-specific t-cells
CN103869082B (zh) * 2014-03-18 2016-02-03 浙江大学 免疫荧光法检测hla-dr表达量评估pbmc抗原呈递能力的方法
EP4270006A3 (en) 2014-06-13 2024-01-10 Immudex ApS General detection and isolation of specific cells by binding of labeled molecules
EP3483179B1 (en) * 2014-06-18 2020-09-16 Albert Einstein College of Medicine Syntac polypeptides and uses thereof
CN105492605A (zh) * 2014-08-01 2016-04-13 比科尔公司 用于免疫检验的病毒样颗粒、用于所述免疫检验的封闭剂、及包含它们的试剂盒
US10676514B2 (en) 2014-08-04 2020-06-09 Oncotherapy Science, Inc. CDCA1-derived peptide and vaccine containing same
CN111925431A (zh) 2014-08-04 2020-11-13 肿瘤疗法科学股份有限公司 Koc1衍生的肽和包含它们的疫苗
ES2856834T3 (es) 2014-08-04 2021-09-28 Oncotherapy Science Inc Péptido derivado de URLC10 y vacuna que contiene el mismo
GB201515351D0 (en) * 2015-08-28 2015-10-14 Cancer Res Technology Antibody
MX2018004308A (es) 2015-10-08 2018-05-01 Oncotherapy Science Inc Peptido derivado de foxm1 y vacuna que lo incluye.
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2018083505A1 (en) 2016-11-07 2018-05-11 Immunocore Limited Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
WO2017201210A1 (en) 2016-05-18 2017-11-23 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
US11320431B2 (en) 2016-06-28 2022-05-03 Technische Universitaet Muenchen Combination of reversible and irreversible cell labeling for analizing receptor-ligand koff rate
US11555177B2 (en) 2016-07-13 2023-01-17 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
WO2018046468A1 (en) 2016-09-06 2018-03-15 F. Hoffmann-La Roche Ag Mhc-bound peptide arrays and methods of use thereof
TWI667034B (zh) * 2016-09-21 2019-08-01 惠眾生技股份有限公司 關刀豆用於製備保護膀胱避免損傷藥劑之用途
WO2018115146A1 (en) 2016-12-21 2018-06-28 Danmarks Tekniske Universitet Antigen presenting scaffolds for immune-cell manipulation
AU2017379900A1 (en) 2016-12-22 2019-06-13 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
SG11202003625VA (en) 2017-11-03 2020-05-28 Aurigene Discovery Tech Ltd Dual inhibitors of tim-3 and pd-1 pathways
JP7378395B2 (ja) 2017-11-06 2023-11-13 オーリジーン オンコロジー リミテッド 免疫調節のためのコンジョイントセラピー
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
MX2020005193A (es) 2018-01-25 2020-08-20 I Mab Biopharma Us Ltd Fusiones de anticuerpo anti-pd-l1 e il-7.
EP3752832A1 (en) 2018-02-12 2020-12-23 10X Genomics, Inc. Methods characterizing multiple analytes from individual cells or cell populations
IL276730B2 (en) * 2018-02-17 2024-08-01 Regeneron Pharma GAN–CNN for MHC peptide binding prediction
WO2019217758A1 (en) 2018-05-10 2019-11-14 10X Genomics, Inc. Methods and systems for molecular library generation
US20230138095A1 (en) 2018-06-20 2023-05-04 Danmarks Tekniske Universitet Scaffolds with stabilized mhc molecules for immune-cell manipulation
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
GB201909509D0 (en) 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
GB201910605D0 (en) * 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
WO2021024742A1 (ja) * 2019-08-06 2021-02-11 国立大学法人筑波大学 細胞傷害アッセイ方法
WO2021122185A1 (en) 2019-12-20 2021-06-24 Miltenyi Biotec B.V. & Co. KG Reversible cell detection via mhc with conjugates having an enzymatically cleavable detection moiety
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
IL296209A (en) 2020-05-12 2022-11-01 Cue Biopharma Inc Multimeric t-cell modulatory polypeptides and methods of using them
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
EP4247968A1 (en) 2020-11-20 2023-09-27 Becton, Dickinson and Company Use of dextramer in single cell analysis
GB202018395D0 (en) 2020-11-23 2021-01-06 Scancell Ltd Immunotherapy
CN116286366B (zh) * 2023-03-15 2024-07-09 齐齐哈尔大学 一种用于碱性微生物检验的微生物分离方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352761A2 (de) * 1988-07-28 1990-01-31 BEHRINGWERKE Aktiengesellschaft Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung
EP0636696A1 (en) * 1992-10-15 1995-02-01 Toray Industries, Inc. Process for producing major histocompatibility antigen class ii protein and material having the same immobilized thereon
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
WO1999014236A1 (en) * 1997-09-16 1999-03-25 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU530410B2 (en) 1978-02-21 1983-07-14 Sintef Preparing aqueous emulsions
NO155316C (no) 1982-04-23 1987-03-11 Sintef Fremgangsmaate for fremstilling av magnetiske polymerpartikler.
GB9007966D0 (en) 1990-04-09 1990-06-06 Dynal As Antigen/anti-antigen cleavage
DE69213240T2 (de) 1991-07-04 1997-04-24 Immunodex K/S, Glostrup Wasserlösliche reagenzien und konjugate auf polymerbasis, die vom divinylsulfon abgeleitete reste enthalten
JP3167415B2 (ja) * 1992-04-30 2001-05-21 オリンパス光学工業株式会社 固相免疫検査における抗原細胞の保存方法
AU3036597A (en) * 1996-05-21 1997-12-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for using peptide complexes/major histocompatibility complex to obtain or purify antigen-specific t cells and to stimulate t cells
FR2751989B1 (fr) * 1996-08-01 1998-10-30 Soc D Rech Et De Dev En Activa Methode d'identification de cellules eucaryotes par fixation desdites cellules sur un support et support pour mettre en oeuvre ladite methode
US5994089A (en) * 1997-05-16 1999-11-30 Coulter International Corp. Simultaneous analyses of white blood cell subsets using multi-color, multi-intensity fluorescent markers in flow cytometry
GB9718463D0 (en) 1997-08-29 1997-11-05 Dynal As Biomolecules
BR9908082A (pt) * 1998-02-19 2000-10-31 Harvard College Proteìna de fusão do complexo de histocompatibilidade principal classe ii, conjugado dos domìnios de ligação do complexo de histocompatibilidade principal multimérico, processos para detectar células t tendo uma especificidade do complexo definido de mhc / peptìdeo, para conferir a um indivìduo imunidade adotiva a um complexo definido de mhc / peptìdeo, para estimular ou ativar as células t reativas a um complexo definido de mhc / peptìdeo, para seletivamente matar células t reativas a um complexo definido de mhc / peptìdeo, para tolerizar um indivìduo humano a um complexo definido de mhc / peptìdeo, e, ácido nucleico isolado
KR20010075108A (ko) 1998-09-14 2001-08-09 라즈 외스테르가아드 페데르센 기능적 면역글로불린 수퍼패밀리 단백질을 생산하는 방법
WO2000023053A2 (en) * 1998-10-20 2000-04-27 Salvatore Albani Artificial antigen-specific cells and related methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0352761A2 (de) * 1988-07-28 1990-01-31 BEHRINGWERKE Aktiengesellschaft Antigenkonstrukte von "Major Histocompatibility Complex" Klasse I Antigenen mit spezifischen Trägermolekülen, ihre Herstellung und Verwendung
EP0636696A1 (en) * 1992-10-15 1995-02-01 Toray Industries, Inc. Process for producing major histocompatibility antigen class ii protein and material having the same immobilized thereon
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
WO1999014236A1 (en) * 1997-09-16 1999-03-25 Oregon Health Sciences University Recombinant mhc molecules useful for manipulation of antigen-specific t-cells

Also Published As

Publication number Publication date
JP2005500257A (ja) 2005-01-06
JP4608184B2 (ja) 2011-01-05
EP1377609A2 (en) 2004-01-07
ES2747357T3 (es) 2020-03-10
AU2002240818B2 (en) 2008-06-19
EP1377609B1 (en) 2015-06-24
DK2336167T3 (da) 2019-09-02
WO2002072631A8 (en) 2002-11-28
AU2008202862A1 (en) 2008-07-24
EP2336167B1 (en) 2019-05-29
EP2336167A1 (en) 2011-06-22
AU2008202862B2 (en) 2011-09-29
AU2002240818C1 (en) 2008-11-06
CA2440773A1 (en) 2002-09-19
NO20034020D0 (no) 2003-09-11
WO2002072631A2 (en) 2002-09-19
WO2002072631A3 (en) 2003-11-06
JP2010248200A (ja) 2010-11-04

Similar Documents

Publication Publication Date Title
NO20034020L (no) Nye MHC molekylforbindelser, og metoder for anvendelse av disse forbindelsene for diagnose og terapi, og anvendelse av MHC molekyler
NO20043246L (no) Nye fremgangsmater til diagnose og behandling av tumorer
NO20030714D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av HER-2/NEU-assosierte maligniteter
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
BR0111125A (pt) Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
NO20012170L (no) Selvstendig, transportabel blodbehandlingsinnretning
NO20055317D0 (no) Fremgangsmate og system for medisinsk undersokelse hjemme
NO20016427D0 (no) Blandinger og fremgangsmåter for behandling av diagnose av lungekreft
NO20041216L (no) Imidazol-4-karboksamidderivater, fremstilling og anvendelse derav for behandling av overvekt
IL172286A0 (en) Portable medical diagnostic apparatus
BR0311672B1 (pt) aparelho de proteção de agulha médica.
NO20053771L (no) Ringromsfluider og fremgangsmater for plassering av de samme
NO20050570L (no) Nye forbindelser, preparater og fremgangsmater for behandling av inflammasjonssykdommer og -tilstander
WO2005014035A3 (en) Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
NO20013002D0 (no) Blandinger og fremgangsmåter for behandling og diagnose av ovariekreft
DE602004024630D1 (de) Ultraschalldiagnosegerät
DE60332649D1 (de) Mehrlumige struktur für eine implantierbare medizinische vorrichtung
DE602004021618D1 (de) Diagnostische testvorrichtung und anwendungsverfahren dafür
DE602004023991D1 (de) Ultraschalldiagnosegerät
AU2003902503A0 (en) Medical Apparatus, Use and Methods
DE10292329D2 (de) Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
NO20054049D0 (no) Fremgangsmate for diagnose og behandling.
IS6077A (is) Efnasambönd og aðferðir til meðhöndlunar á asma, ofnæmi og bólgutruflunum
IS7163A (is) Aðferðir til meðhöndlunar á lungnasjúkdómi

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: AGILENT TECHNOLOGIES, US

CREP Change of representative

Representative=s name: BRYN AARFLOT AS, STORTINGSGATA 8, 0161 OSLO, NORGE

MK1K Patent expired
FC2A Withdrawal, rejection or dismissal of laid open patent application